* Obtains authorization from European regulatory authorities
to restart Ovasave phase IIb clinical trial
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
The post BRIEF-Txcell obtains authorization to restart Ovasave phase IIb clinical trial appeared first on NASDAQ.